Free tool
FAERS Monitor: Pheburane
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 216513 or its brand name (Pheburane, Sodium Phenylbutyrate). Reports on generic versions are filed under their own applications.
Reports
177
Serious
122
69% of reports
Hospitalization
60
Death reported
46
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death24
- off label use21
- hyperammonaemia20
- nausea20
- diarrhoea18
- decreased appetite16
- ammonia increased13
- vomiting13
- product use complaint12
- retching12
- drug ineffective11
- fatigue10
- pyrexia9
- abdominal pain8
- adverse event7
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 4 |
| 2010 | 5 |
| 2011 | 3 |
| 2012 | 15 |
| 2013 | 4 |
| 2014 | 6 |
| 2015 | 8 |
| 2016 | 8 |
| 2017 | 9 |
| 2018 | 2 |
| 2019 | 4 |
| 2020 | 4 |
| 2021 | 7 |
| 2022 | 10 |
| 2023 | 30 |
| 2024 | 24 |
| 2025 | 21 |
| 2026 | 10 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,982 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hyperammonaemiaSignal | 20 | 477.1 | 315.5 | 8,999 |
| ammonia increasedSignal | 13 | 303.6 | 179.8 | 3,615 |
| product use complaintSignal | 12 | 90.6 | 52.4 | 975 |
| retchingSignal | 12 | 66.9 | 38.7 | 715 |
| adverse eventSignal | 7 | 9.0 | 4.4 | 42 |
| decreased appetiteSignal | 16 | 8.2 | 5.1 | 95 |
| abdominal painSignal | 8 | 4.1 | 2.1 | 16 |
| diarrhoeaSignal | 18 | 3.3 | 2.1 | 28 |
| deathSignal | 24 | 3.3 | 2.3 | 38 |
| vomitingSignal | 13 | 3.3 | 1.9 | 19 |
| pyrexiaSignal | 9 | 3.1 | 1.6 | 11 |
| nauseaSignal | 20 | 3.0 | 2.0 | 26 |
| off label useSignal | 21 | 2.8 | 1.9 | 24 |
| fatigue | 10 | 1.5 | 0.8 | 1 |
| drug ineffective | 11 | 1.0 | 0.6 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.